Renee' Odehnal In this session, the learner will examine some of the common practice and education gaps found in the clinical setting. We will discuss ways in which we can identify the need for education and help cultivate a greater understanding of evidence based practices for those with various backgrounds, experience levels and learning styles. Review the current standards, guidelines and recommendations for evidence based care and maintenance of vascular access devices.
Marcia Wise This presentation will review the evidence and describe the benefits of adding tissue adhesives (TA) to the tool box of preventative technologies you can use to improve the vascular access experience for patients. Publications over the last decade reveal several purposes and favorable outcomes when TA are used with both peripheral and central vascular access devices (VAD). Objectives include identifying vascular access device complications, defining the components and characteristics of tissue adhesives and analyze the clinical outcomes with tissue adhesives used with VADs.
Robin Belle In this presentation, you will learn the indications and administration of intravenous immunoglobulin (IgG). IVIG therapy is used to treat conditions that include primary immunodeficiency, idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain-Barré syndrome and in certain other infections when a more specific immunoglobulin is not available. This session will prepare and educate the infusion nurse about indications, complications, risks and benefits when administering IVIG therapy for patients with these conditions
Mark Rowe The learner will understand the difference between subcutaneous engineered securement device (SESD) and adhesive engineered securement devices (AESD). This presentation will review retrospective methodology used to accumulate data and emphasize the risk reduction comparison, as related to securement device selection, as it relates to CLABSI.
Kathy Kokotis The attendee will understand the changes made to the INS standards regarding vesicants and irritants and how to apply this knowledge to device selection. The attendee will have an understanding on the limitations of the meta-analysis on thrombosis in the ICU and how that impacts vascular access decision-making on the high risk ICU patient. A case study on vascular access decision making and MAGIC will be discussed. At the end of the presentation the attendee will be able to evaluate how MAGIC applies to their current high risk patient population and vascular decision making.